TUSTIN, CA--(Marketwire - October 20, 2010) -
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM
), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from a preclinical study of bavituximab have been accepted for presentation at the 2010 Chemical and Biological Defense Science and Technology Conference, to be held November 15-19, 2010 in Orlando, Florida.
"Targeting of Anionic Phospholipids Exposed on Infected Cells and Virions: Potential broad-Spectrum Antiviral Therapy" (abstract T02-003) will be presented in a poster session on Tuesday, November 16, 2010 from 6:00 pm to 8:00 pm EST.
For additional information about the conference, please visit http://cbdstconf2010.sainc.com/general_information/default.aspx
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.